Walburga Engel-Riedel

6.7k total citations
43 papers, 795 citations indexed

About

Walburga Engel-Riedel is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Walburga Engel-Riedel has authored 43 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Walburga Engel-Riedel's work include Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (18 papers) and Lung Cancer Research Studies (16 papers). Walburga Engel-Riedel is often cited by papers focused on Lung Cancer Treatments and Mutations (28 papers), Lung Cancer Diagnosis and Treatment (18 papers) and Lung Cancer Research Studies (16 papers). Walburga Engel-Riedel collaborates with scholars based in Germany, France and United States. Walburga Engel-Riedel's co-authors include Erich Stoelben, Werner Mühlnickel, Péter Fritz, Jens Kollmeier, Monika Serke, Thomas Zander, Michael Thomas, Jürgen Wolf, Christian Schumann and Sascha Ansén and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Walburga Engel-Riedel

43 papers receiving 783 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Walburga Engel-Riedel Germany 15 556 411 140 138 136 43 795
J. Le Treut France 10 701 1.3× 496 1.2× 112 0.8× 84 0.6× 91 0.7× 22 898
Felipe Couñago Spain 16 477 0.9× 325 0.8× 113 0.8× 218 1.6× 100 0.7× 110 812
Yenting Ngai United Kingdom 9 381 0.7× 273 0.7× 90 0.6× 89 0.6× 78 0.6× 17 557
Ligang Xing China 13 284 0.5× 169 0.4× 81 0.6× 241 1.7× 88 0.6× 44 594
Olga C.J. Schuurbiers Netherlands 16 652 1.2× 226 0.5× 231 1.6× 261 1.9× 239 1.8× 28 1.0k
Evan C. Osmundson United States 14 181 0.3× 222 0.5× 114 0.8× 83 0.6× 207 1.5× 43 651
Imogen Locke United Kingdom 16 301 0.5× 208 0.5× 288 2.1× 246 1.8× 134 1.0× 39 798
Boone Goodgame United States 14 400 0.7× 264 0.6× 227 1.6× 232 1.7× 212 1.6× 39 879
Navita Somaiah United Kingdom 16 203 0.4× 272 0.7× 331 2.4× 312 2.3× 172 1.3× 51 760

Countries citing papers authored by Walburga Engel-Riedel

Since Specialization
Citations

This map shows the geographic impact of Walburga Engel-Riedel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walburga Engel-Riedel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walburga Engel-Riedel more than expected).

Fields of papers citing papers by Walburga Engel-Riedel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walburga Engel-Riedel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walburga Engel-Riedel. The network helps show where Walburga Engel-Riedel may publish in the future.

Co-authorship network of co-authors of Walburga Engel-Riedel

This figure shows the co-authorship network connecting the top 25 collaborators of Walburga Engel-Riedel. A scholar is included among the top collaborators of Walburga Engel-Riedel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walburga Engel-Riedel. Walburga Engel-Riedel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fischer, Rieke, Julie George, Hans Anton Schloesser, et al.. (2024). BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhigh cohort.. Journal of Clinical Oncology. 42(16_suppl). 8099–8099. 1 indexed citations
2.
Engel-Riedel, Walburga, J. Richard Trout, Richard D. Huhn, et al.. (2018). A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer. Journal for ImmunoTherapy of Cancer. 6(1). 16–16. 19 indexed citations
3.
Schuette, Wolfgang, Claus-Peter Schneider, Walburga Engel-Riedel, et al.. (2017). 65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer. SHILAP Revista de lepidopterología. Volume 8. 217–229. 8 indexed citations
4.
5.
Kreuter, Michael, Johan Vansteenkiste, Jürgen R. Fischer, et al.. (2016). Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study). Journal of Thoracic Oncology. 11(1). 85–93. 23 indexed citations
6.
Schmid‐Bindert, Gerald, Walburga Engel-Riedel, Martin Reck, et al.. (2015). A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Lung Cancer. 90(3). 397–404. 9 indexed citations
7.
Braun, Ada, Walburga Engel-Riedel, Folker Schneller, et al.. (2015). Efficacy and Safety of Imprime Pgg, a Novel Innate Immune Modulator, in Combination with Bevacizumab (BEV), Carboplatin and Paclitaxel for the 1St-Line Treatment of Stage Iv Nsclc. Annals of Oncology. 26. i29–i29. 2 indexed citations
8.
9.
Magnet, Friederike Sophie, et al.. (2014). Adjuvant treatment of completely resected stage IB-IIIA non-small-cell lung cancer. A retrospective study with cisplatin or carboplatin and oral vinorelbine.. Journal of Clinical Oncology. 32(15_suppl). e18505–e18505. 2 indexed citations
10.
Schildgen, Verena, Jessica Lüsebrink, Walburga Engel-Riedel, et al.. (2013). Identification of Uncommon PIK3CA Mutations in Lung Cancer by Using Pyrosequencing. Diagnostic Molecular Pathology. 22(1). 22–27. 5 indexed citations
11.
Kreuter, Michael, Johan Vansteenkiste, J.R. Fischer, et al.. (2012). Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. Annals of Oncology. 24(4). 986–992. 56 indexed citations
12.
Zander, Thomas, Lukas C. Heukamp, Marc Bos, et al.. (2012). Regional screening network for characterization of the molecular epidemiology of non-small cell lung cancer (NSCLC) and implementation of personalized treatment.. Journal of Clinical Oncology. 30(15_suppl). CRA10529–CRA10529. 7 indexed citations
13.
Zander, Thomas, Andrea Hofmann, Andrea Staratschek‐Jox, et al.. (2011). Blood-Based Gene Expression Signatures in Non–Small Cell Lung Cancer. Clinical Cancer Research. 17(10). 3360–3367. 51 indexed citations
14.
Kreuter, Michael, Johan Vansteenkiste, J.R. Fischer, et al.. (2011). Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT.. Journal of Clinical Oncology. 29(15_suppl). 7002–7002. 3 indexed citations
15.
Querings, Silvia, Janine Altmüller, Sascha Ansén, et al.. (2011). Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS ONE. 6(5). e19601–e19601. 97 indexed citations
16.
Nagel, S., O Kellner, Walburga Engel-Riedel, et al.. (2011). Addition of Darbepoetin Alfa to Dose-Dense Chemotherapy: Results From a Randomized Phase II Trial in Small-Cell Lung Cancer Patients Receiving Carboplatin Plus Etoposide. Clinical Lung Cancer. 12(1). 62–69. 12 indexed citations
17.
Fritz, Péter, Thomas Blaschke, Werner Mühlnickel, et al.. (2007). Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer. 60(2). 193–199. 63 indexed citations
18.
Laack, Eckart, Andreas Krüll, Walburga Engel-Riedel, et al.. (2007). A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC). Lung Cancer. 57(2). 181–186. 3 indexed citations
19.
Fritz, Péter, et al.. (2006). Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiation Oncology. 1(1). 30–30. 83 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J. Le Treut Breakdown of academic impact, for papers by Felipe Couñago Breakdown of academic impact, for papers by Yenting Ngai Breakdown of academic impact, for papers by Ligang Xing Breakdown of academic impact, for papers by Olga C.J. Schuurbiers Breakdown of academic impact, for papers by Evan C. Osmundson Breakdown of academic impact, for papers by Imogen Locke Breakdown of academic impact, for papers by Boone Goodgame Breakdown of academic impact, for papers by Navita Somaiah
Rankless by CCL
2026